Sitagliptin Not Linked to Higher Fracture Risk in Diabetes

This article originally appeared here.
Share this content:
Sitagliptin Not Linked to Higher Fracture Risk in Diabetes
Sitagliptin Not Linked to Higher Fracture Risk in Diabetes

WEDNESDAY, Sept. 14, 2016 (HealthDay News) -- Patients with diabetes often have fractures, but sitagliptin is not associated with increased fracture risk, according to a study published online Sept. 8 in Diabetes, Obesity and Metabolism.

Robert G. Josse, M.B.B.S., from the University of Toronto, and colleagues examined fracture incidence in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Data were included from 14,671 TECOS patients who were randomized to sitagliptin (7,332 patients) or placebo (7,339 patients).

The researchers found that 2.6 percent of patients had a fracture during 43,222 person-years' follow-up, of which 146 were major osteoporotic fractures. There was an independent association between fracture risk and older age, female sex, white race, and lower diastolic blood pressure (all P < 0.001), as well as diabetic neuropathy (P = 0.003). Compared with placebo, sitagliptin was not linked to increased fracture risk (P = 0.745), major osteoporotic fractures (P = 0.673), or hip fractures (P = 0.761). Increased fracture risk was seen in association with insulin therapy (hazard ratio, 1.4; P = 0.035), and metformin was linked to decreased risk (hazard ratio, 0.76; P = 0.035).

"Fractures were common among TECOS patients with diabetes, but not related to sitagliptin therapy," the authors write. "Insulin and metformin treatment were associated with increased and decreased fracture risks, respectively."

Several authors disclosed financial ties to pharmaceutical companies, including Merck, which manufactures sitagliptin and funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »